Skip to content

Lithotripsy for the Treatment of Gallstones

Biliary Lithotripsy in Combination With Actigall Versus Actigall Monotherapy for the Treatment of Symptomatic Cholesterol Gallstones

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00042549
Enrollment
184
Registered
2002-08-05
Start date
2002-05-31
Completion date
Unknown
Last updated
2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholelithiasis

Keywords

Gallstones, Gallstone, Biliary stones, Gallbladder stones, Gallbladder, Lithotripsy, Cholelithiasis, ESWL, Shock wave, Shock waves, shockwaves, shockwave

Brief summary

The purpose of this study is to determine the effectiveness and safety of using the Medstone lithotripter to treat single non-calcified gallstones from 4 to 20 mm in diameter.

Detailed description

This study is a randomized, single-masked controlled trial in which the combination therapy of lithotripsy and the bile acid drug Actigall is compared to monotherapy with only Actigall. The primary objectives are, 1) To determine whether the use of the Medstone STS Lithotripter system in combination with the orally administered drug Actigall is more effective (as measured by percentages of stone free patients 6 months after randomization) in reducing single non-calcified radiolucent gallstones (from 4 to 20mm in diameter) than use of Actigall alone, and 2) To demonstrate that use of the Medstone lithotripsy system is safe (as measured by incidence of adverse events) for the intended purpose, when operated according to its labeling.

Interventions

Sponsors

Medstone International
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* History of biliary pain * Evidence of a single noncalcified, radiolucent gallstone between 4 and 20 mm (inclusive) diameter * HIDA scan demonstrating patency of cystic bile duct * No cardiac pacemaker * No allergy to radioopaque dye, iodine, bile acids * No spontaneous or iatrogenic bleeding disorder * No current or prior bile duct obstruction, cholangitis, pancreatitis, or cholecystitis * Not pregnant

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026